scholarly journals TKTL1 as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma and Its Correlation with FDG-PET-CT

Oncology ◽  
2020 ◽  
pp. 1-9
Author(s):  
Kaisa Ahopelto ◽  
Kapo Saukkonen ◽  
Jaana Hagström ◽  
Saila Kauhanen ◽  
Hanna Seppänen ◽  
...  

<b><i>Introduction:</i></b> Glucose metabolism in cancer cells differs from noncancerous cells. The expression of transketolase-like protein 1 (TKTL1), a key enzyme in the glucose metabolism of cancer cells, predicts poor prognosis in several cancer types. We studied TKTL1 as a prognostic tool and whether TKTL1 expression correlates with 18F-FDG-PET-CT among patients with pancreatic ductal adenocarcinoma (PDAC). <b><i>Methods:</i></b> This retrospective study examined two PDAC patient cohorts: 168 patients operated on at Helsinki University Hospital between 2001 and 2011, and 20 patients with FDG-PET-CT results available from the Auria Biobank. We used immunohistochemistry for TKTL1 expression, combining results with clinicopathological data. <b><i>Results:</i></b> Five-year disease-specific survival (DSS) was slightly but not significantly better in patients with a high versus low TKTL1 expression, with DSS of 28.0 versus 17.3%, respectively (<i>p</i> = 0.123). TKTL1 served as a marker of a better prognosis in patients over 65 years old (<i>p</i> = 0.012) and among those with TNM class M1 (<i>p</i> = 0.018), stage IV disease (<i>p</i> = 0.027), or perivascular invasion (<i>p</i> = 0.008). <b><i>Conclusions:</i></b> Our study shows that TKTL1 cannot be used as a prognostic factor in PDAC with the exception of elderly patients and those with advanced disease. The correlation of TKTL1 with 18F-FDG-PET-CT requires further study in a larger patient cohort.

Diagnostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1042
Author(s):  
Annachiara Arnone ◽  
Riccardo Laudicella ◽  
Federico Caobelli ◽  
Priscilla Guglielmo ◽  
Marianna Spallino ◽  
...  

In this review, the performance of fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in the diagnostic workup of pancreatic ductal adenocarcinoma (PDAC) is evaluated. A comprehensive literature search up to September 2020 was performed, selecting studies with the presence of: sample size ≥10 patients and index test (i.e., “FDG” or “18F-FDG” AND “pancreatic adenocarcinoma” or “pancreas cancer” AND “PET” or “positron emission tomography”). The methodological quality was evaluated using the revised quality assessment of diagnostic accuracy studies (QUADAS-2) tool and presented according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Basic data (authors, year of publication, country and study design), patients’ characteristics (number of enrolled subjects and age), disease phase, type of treatment and grading were retrieved. Forty-six articles met the adopted research criteria. The articles were divided according to the considered clinical context. Namely, besides conventional anatomical imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), molecular imaging with FDG PET/CT is an important tool in PDAC, for all disease stages. Further prospective studies will be necessary to confirm the cost-effectiveness of such imaging techniques by testing its real potential improvement in the clinical management of PDAC.


2017 ◽  
Vol 43 (2) ◽  
pp. 415-434 ◽  
Author(s):  
Randy Yeh ◽  
Laurent Dercle ◽  
Ishan Garg ◽  
Zhen Jane Wang ◽  
David M. Hough ◽  
...  

Pancreatology ◽  
2013 ◽  
Vol 13 (4) ◽  
pp. S48
Author(s):  
Kwang Hyun Chung ◽  
Sang Hyub Lee ◽  
Joo Kyung Park ◽  
Jin-Hyeok Hwang

2021 ◽  
pp. jnumed.121.261952
Author(s):  
Matthias R. Benz ◽  
Wesley R. Armstrong ◽  
Francesco Ceci ◽  
Giulia Polverari ◽  
Timothy R. Donahue ◽  
...  

Biomedicines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 561
Author(s):  
Imke E. Karsten ◽  
Gabriele Reinartz ◽  
Michaela Pixberg ◽  
Kai Kröger ◽  
Michael Oertel ◽  
...  

This retrospective study examined the role of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) in stage-related therapy of follicular lymphomas (FL). Twelve patients each in stages I and II, 13 in stage III and 11 in stage IV were treated in the Department of Radiation Oncology, University Hospital of Muenster, Germany from 2004 to 2016. Radiotherapy (RT), as well as additional chemoimmunotherapy were analyzed with a median follow-up of 87.6 months. Ultrasound (US), CT and 18F-FDG-PET/CT were used to determine progression-free survival (PFS), overall survival (OS) and lymphoma-specific survival (LSS) over 5- and 10- years. 23 of 24 patients with stage I/II (95.8%) had complete remissions (CR) and 17 of 24 patients with stages III/IV FL showed CR (70.8%). 5- and 10-year PFS in stages I/II was 90.0%/78.1% vs. 44.3%/28.5% in stages III/IV. 5- and 10-year OS rates in stages I/II was 100%/93.3% vs. 53.7%/48.4% in stages III/IV. 5- and 10-year LSS of stages I/II was 100%/93.8% vs. 69.2%/62.3% in stages III/IV. FL of stages I/II, staged by 18F-FDG-PET/CT, revealed better survival rates and lower risk of recurrence compared to studies without PET/CT-staging. Especially, patients with PET/CT proven stage I disease showed significantly better survival and lower relapses rates after RT.


Medicine ◽  
2020 ◽  
Vol 99 (11) ◽  
pp. e19504 ◽  
Author(s):  
Li Wang ◽  
Ping Dong ◽  
Weiguo Wang ◽  
Mao Li ◽  
Weiming Hu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document